Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Xenon licenses pain compounds and companion diagnostics to Genentech; terminated

Executive Summary

Canadian drug discovery company Xenon Pharmaceuticals Inc. has licensed Genentech Inc. exclusive rights to develop and sell drug candidates for pain, including oral inhibitors of the sodium Nav 1.7 channel. Genentech also received a nonexclusive license to companion diagnostics.
Deal Industry
  • Biotechnology
    • Large Molecule
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Intra-Biotech Deal
    • Includes Royalty or Profit Split Information
    • R+D and Marketing-Licensing
    • Includes Contract

Related Companies

Advertisement
UsernamePublicRestriction

Register